Streamex Corp – Company Overview and Recent Regulatory Filings
Company: Streamex Corp (NASDAQ: STEX)
Sector: Health Care
Industry: Health Care Equipment & Supplies
Currency: USD
Market Capitalisation: $799.65 million
Financial Snapshot (as of 13 Oct 2025)
- Closing Share Price: $5.84
- 52‑Week High: $14.11 (7 Jul 2025)
- 52‑Week Low: $0.30 (16 Oct 2024)
- Price‑to‑Earnings Ratio: –5.85
Streamex Corp is a U.S. medical‑technology company that develops signal‑processing solutions for cardiac catheter ablation procedures. Its products aim to improve outcomes for complex arrhythmias such as ventricular tachycardia, positioning the company within the broader health‑care equipment and supplies sector.
Recent Regulatory Filings
All filings reported on 15 Oct 2025 and 14 Oct 2025 are routine compliance documents that do not convey substantive corporate developments. The documents include:
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018
- Issued by the Registrar of Companies (RTA) on 15 Oct 2025.
- Confirms compliance with statutory registration requirements.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
- Also issued on 15 Oct 2025.
- Affirms that the company’s securities are correctly registered with BSE and NSE.
Re‑appointment of Statutory Auditor
- M/s PVAR & Associates were re‑appointed for the FY 2025‑26 on 14 Oct 2025.
- No change in audit fees or audit opinion was disclosed.
Security Cover Certificate
- Issued on 14 Oct 2025, confirming the maintenance of required security cover for listed securities.
Investor Presentation and Analyst Meeting Outcomes
- Documents dated 14 Oct 2025 summarise results presented to investors and analysts.
- No material financial results or strategic announcements were disclosed in these filings.
Market Context
- The company’s share price remains well below its 52‑week high, reflecting market volatility rather than fundamental change.
- The negative P/E ratio indicates that the company is not yet generating positive earnings per share, a common situation for early‑stage medical‑technology firms focused on product development and regulatory approvals.
Conclusion
The latest regulatory disclosures from Streamex Corp on 14–15 Oct 2025 are standard corporate compliance documents. They confirm the company’s continued listing status on Nasdaq, adherence to SEBI and BSE/NSE regulations, and the re‑appointment of its statutory auditor. No new financial results, product launches, or strategic initiatives were reported in these filings.
